ArticleTrials2025

Regorafenib versus local standard of care in patients with grade 2-3 meningioma no longer eligible for loco-regional treatments: a phase II randomized controlled trial (the MIRAGE study).

Alberto Bosio et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.